These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3147 related articles for article (PubMed ID: 7705956)

  • 1. Rejection of mouse melanoma elicited by local secretion of interleukin-2: implicating macrophages without T cells or natural killer cells in tumor rejection.
    Hara I; Nguyen H; Takechi Y; Gansbacher B; Chapman PB; Houghton AN
    Int J Cancer; 1995 Apr; 61(2):253-60. PubMed ID: 7705956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of myeloid dendritic cells retrovirally transduced to express mammalian or viral interleukin-10 on cytotoxic T lymphocyte and natural killer cell functions and resistance to tumor growth.
    Takayama T; Tahara H; Thomson AW
    Transplantation; 2001 May; 71(9):1334-40. PubMed ID: 11397973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization with interleukin-2/interferon-gamma double cytokine-secreting allogeneic fibroblasts prolongs the survival of mice with melanoma.
    Kim TS; Xu WS; Sun T; Cohen EP
    Melanoma Res; 1995 Aug; 5(4):217-27. PubMed ID: 7496156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases.
    Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L
    Cancer Res; 1995 Nov; 55(21):4941-9. PubMed ID: 7585534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2.
    Chen PW; Ananthaswamy HN
    J Immunol; 1993 Jul; 151(1):244-55. PubMed ID: 8326126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour cell vaccines that secrete interleukin-2 (IL-2) and interferon gamma (IFN gamma) are recognised by T cells while resisting destruction by natural killer (NK) cells.
    Zier KS; Gansbacher B
    Eur J Cancer; 1996 Jul; 32A(8):1408-12. PubMed ID: 8869107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A role for CD4+ NK1.1+ T lymphocytes as major histocompatibility complex class II independent helper cells in the generation of CD8+ effector function against intracellular infection.
    Denkers EY; Scharton-Kersten T; Barbieri S; Caspar P; Sher A
    J Exp Med; 1996 Jul; 184(1):131-9. PubMed ID: 8691126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rejection of tumors in mice with severe combined immunodeficiency syndrome determined by the major histocompatibility complex. Class I expression on the graft.
    Glas R; Waldenström M; Höglund P; Klein G; Kärre K; Ljunggren HG
    Cancer Res; 1995 May; 55(9):1911-6. PubMed ID: 7728758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma.
    Hock H; Dorsch M; Kunzendorf U; Qin Z; Diamantstein T; Blankenstein T
    Proc Natl Acad Sci U S A; 1993 Apr; 90(7):2774-8. PubMed ID: 8464888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.
    Hu HM; Winter H; Urba WJ; Fox BA
    J Immunol; 2000 Oct; 165(8):4246-53. PubMed ID: 11035058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracranial paracrine interleukin-2 therapy stimulates prolonged antitumor immunity that extends outside the central nervous system.
    Ewend MG; Thompson RC; Anderson R; Sills AK; Staveley-O'Carroll K; Tyler BM; Hanes J; Brat D; Thomas M; Jaffee EM; Pardoll DM; Brem H
    J Immunother; 2000; 23(4):438-48. PubMed ID: 10916753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-induced suppression of interferon-gamma production and enhancement of interleukin-10 production by natural killer (NK) cells: paralleled to CD4+ T cells.
    Wei H; Zheng X; Lou D; Zhang L; Zhang R; Sun R; Tian Z
    Mol Immunol; 2005 May; 42(9):1023-31. PubMed ID: 15829292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The combined action of IL-15 and IL-12 gene transfer can induce tumor cell rejection without T and NK cell involvement.
    Di Carlo E; Comes A; Basso S; De Ambrosis A; Meazza R; Musiani P; Moelling K; Albini A; Ferrini S
    J Immunol; 2000 Sep; 165(6):3111-8. PubMed ID: 10975824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy.
    Becker JC; Pancook JD; Gillies SD; Furukawa K; Reisfeld RA
    J Exp Med; 1996 May; 183(5):2361-6. PubMed ID: 8642346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunologic evaluation of spontaneous regression of an intraocular murine melanoma.
    Knisely TL; Niederkorn JY
    Invest Ophthalmol Vis Sci; 1990 Feb; 31(2):247-57. PubMed ID: 2154414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
    Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M
    Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression.
    Levitsky HI; Lazenby A; Hayashi RJ; Pardoll DM
    J Exp Med; 1994 Apr; 179(4):1215-24. PubMed ID: 7908321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The natural immune response to inhaled soluble protein antigens involves major histocompatibility complex (MHC) class I-restricted CD8+ T cell-mediated but MHC class II-restricted CD4+ T cell-dependent immune deviation resulting in selective suppression of immunoglobulin E production.
    McMenamin C; Holt PG
    J Exp Med; 1993 Sep; 178(3):889-99. PubMed ID: 8102390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization of mice with allogeneic fibroblasts genetically modified for interleukin-2-secretion and expression of melanoma-associated antigens stimulate predetermined classes of anti-melanoma effector cells.
    Kim TS; Cohen EP
    J Immunother Emphasis Tumor Immunol; 1994 Jul; 16(1):24-35. PubMed ID: 8081557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-2 augmented activation of tumor associated macrophage plays the main role in MHC class I in vivo induction in tumor cells that are MHC negative in vitro.
    Ouyang GF; Saio M; Suwa T; Imai H; Nakagawa J; Nonaka K; Umemura N; Kijima M; Takami T
    Int J Oncol; 2006 May; 28(5):1201-8. PubMed ID: 16596236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 158.